Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6801082 | 0.88 | ADAM17 (0.62) | ADAM17MMP13 | |
| SCHEMBL6804923 | 0.86 | ADAM17 (0.58) | ADAM17 | |
| SCHEMBL6803499 | 0.86 | ADAM17 (0.63) | ADAM17MMP13 | |
| SCHEMBL6809945 | 0.84 | ADAM17 (0.63) | ADAM17MMP13 | |
| SCHEMBL6804637 | 0.84 | ADAM17 (0.59) | ADAM17 | |
| SCHEMBL7057241 | 0.82 | ADAM17 (0.76) | ADAM17MMP13 | |
| SCHEMBL7058790 | 0.76 | MMP1 (0.65) | ADAM17MMP13 | |
| SCHEMBL7055340 | 0.74 | ADAM17 (0.62) | ADAM17MMP13 | |
| SCHEMBL6804255 | 0.73 | ADAM17 (0.61) | ADAM17 | |
| SCHEMBL6987107 | 0.72 | ADAM17 (0.70) | ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130257-A1 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | claimed |
| US-6770647-B2 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-03 | — | — | US | disclosed |
| US-20030130257-A1 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130257-A1 | Bicyclic hydroxamates as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) | ADAMTS1, ADAM17, MMP1 | ADAM17 2/4885MMP13 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.